Key result
Treatment with high-dose melphalan and autologous peripheral blood stem cell transplantation improved muscle strength in a 27-year-old man with sporadic late-onset nemaline myopathy.
Why the study?
Does high-dose melphalan and auto-PBSCT improve muscle strength in a young adult with SLONM and monoclonal gammopathy?
Case Report (n=1)
Does high-dose melphalan and auto-PBSCT improve muscle strength in a young adult with SLONM and monoclonal gammopathy?
High-dose melphalan and auto-PBSCT can successfully treat sporadic late-onset nemaline myopathy associated with monoclonal gammopathy in young adults.
Does not support routine auto-PBSCT use in SLONM; leaves open benefit pending controlled trials.
INTRODUCTION: Sporadic late-onset nemaline myopathy (SLONM) is a rare intractable acquired myopathy characterized by progressive muscle weakness and atrophy, usually with middle to late adult onset. Autologous peripheral blood stem cell transplantation (auto-PBSCT) has been reported to be a promising treatment for SLONM. METHODS: In this study we performed clinical characterization, muscle histopathological analysis, and muscle power monitoring after auto-PBSCT in a 27-year-old HIV-negative man with monoclonal gammopathy. RESULTS: He showed improved muscle strength after treatment with high-dose melphalan and auto-PBSCT. CONCLUSIONS: Considering the recent reports of successful treatment of SLONM, early and correct diagnosis of this condition in association with monoclonal gammopathy is important. SLONM should be added to the list of diseases to consider in the differential diagnosis of progressive muscle weakness with young adult onset.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2014) conducted a case report in Sporadic late-onset nemaline myopathy (SLONM) (n=1). High-dose melphalan and autologous peripheral blood stem cell transplantation (auto-PBSCT) was evaluated on Muscle strength. Treatment with high-dose melphalan and autologous peripheral blood stem cell transplantation improved muscle strength in a 27-year-old man with sporadic late-onset nemaline myopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: